Search

The combination of iodoplumbate with xanthene dye (Rhodamine B, RhB) gives rise to a new hybrid [(RhB)(PbI3)(DMF)]n (1, DMF = N,N′-dimethylformamide), which was synthesized using solution method. The (PbI3)nn− chain is constructed from face-sharing PbI6 octahedra. The major central xanthene plane in RhB is twisted with the dihedral angle between two benzene rings of 10.08°, which might be driven by the strong C–H···I hydrogen bonds and C–H···π interactions between two moieties. Driven by these strong non-covalent interactions, broader adsorption zone, distinct dual fluorescence with warm white emission and high photocurrent response can be detected, which was further explained by theoretical calculation. [ABSTRACT FROM AUTHOR]

In the title compound, {[Cu(C15H11ClN2O3)(C4H9NO)] n, the CuII cation has square-pyramidal geometry. The morpholine ligand serves as a bridge to link two symmetry-related metal atoms, resulting in an infinite chain structure along the a axis. Adjacent chains are extended into a two-dimensional layered structure via hydrogen bonds formed between morpholine and amide N atoms [N-H...N = 2.971 (3) Å]. [ABSTRACT FROM AUTHOR]

In the title compound, [Cd(C4H13N3)2](C10H6O6S2), the Cd atom, located on an inversion centre, is six-coordinated by two diethyl­enetriamine ligands. The anion is centrosymmetric. The metal complex cations are connected to naphthalene-1,5-disulfonate anions via weak self-complementary N—H⋯O hydrogen bonds into two-dimensional extended sheets, which are further linked into three-dimensional networks with channels along the a axis. [ABSTRACT FROM AUTHOR]

Improvement in managing HPV‐positive women is urgently needed. Based on a population‐based study which included 2112 women aged 49 to 69 from Shanxi, China, we aimed to evaluate the clinical performance of multiple triage strategies based on liquid‐based cytology (LBC), p16INK4a, viral load and partial genotyping, as a single or combined strategy for detecting cervical intraepithelial neoplasia grade 2/3 or higher (CIN2+/CIN3+) in women who tested positive by Hybrid Capture 2 (HC2). Among 452 HC2‐positive women, the test positivity of LBC (ASC‐US+), p16INK4a, HPV16/18 and HPV16/18/31/33/45 were 39.6%, 38.5%, 18.0% and 40.0%, respectively. Compared to LBC (ASC‐US+) triage, a single triage strategies using p16INK4a or extended genotyping (SureX HPV16/18/31/33/45) achieved comparable sensitivity (relative sensitivity: 1.08, 95% confidence interval [CI]: 0.93‐1.26 and 0.96, 95% CI: 0.76‐1.22) and specificity (relative specificity: 1.05, 95% CI: 0.96‐1.14 and 1.02, 95% CI: 0.92‐1.14) for CIN3+. Viral load triage using a ≥50 RLU/CO cut‐point also yielded similar results with LBC (ASC‐US+). Among combined triage strategies, HPV16/18 genotyping with reflex p16INK4a showed higher sensitivity and slightly lower specificity than LBC (ASC‐US+) for CIN3+ detection, however, the differences were not statistically significant. Of note, after a negative result by p16INK4a or LBC among HPV16/18 negative women, the posttest probability of CIN3+ was lower than 1%. Our study suggested that p16INK4a, extended genotyping and increased viral load cut‐point could be promising alternatives to cytology triage. Combined triage algorithms of HPV16/18 with reflex p16INK4a or cytology, if negative, are associated with the substantial low posttest risk sufficient to release women to next screening round. What's new? Cytology triage is widely used to manage the care of women with positive human papillomavirus (HPV) results following HPV‐based screening. Challenges with cytology in low‐resource settings, however, has fueled the development of other triage strategies. Whether these strategies are superior to cytology remains unclear. In this population‐based evaluation, promising alternatives to cytology triage were identified, including p16INK4a biomarker testing, extended genotyping, and viral load with increased cut‐point. These methods were especially suitable for settings that lack trained cytologists. Combined HPV16/18 with reflex p16INK4a or cytology provided optimal risk stratification, enabling double‐negative cases to be released to routine screening. [ABSTRACT FROM AUTHOR]

As China's population ages, the importance of determining prevalence of cervical disease and accurate cervical cancer screening strategies for postmenopausal women is increasing. Seventeen population-based studies were analyzed to determine prevalence of cervical neoplasia in postmenopausal women. All women underwent HPV DNA testing, visual inspection with acetic acid (VIA) and cytology testing. Diagnostic values for primary and combinations screening methods included sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), referral rate and area under curve (AUC) were calculated using directed biopsy or four quadrants biopsy as reference standard. Premenopausal and postmenopausal women had equal HPV infection and cervical neoplasia rates ( p > 0.05). HPV DNA testing CIN3+ sensitivity, specificity, PPV, NPV, referral rate and AUC were 97.9% (95% CI: 90.2-99.9%), 84.2% (95% CI: 82.8-85.5%), 9.9% (95% CI: 7.4-12.8%), 100% (95% CI: 99.8-100%), 17.2% (95% CI: 15.9-18.7%), 0.911, respectively. VIA values were 41.7% (95% CI: 28.4-55.9%), 94.5% (95% CI: 93.6-95.3%), 11.8% (95% CI: 7.5-17.3%), 98.9% (95% CI: 98.5-99.3%), 6.2% (95% CI: 5.3-7.1%) and 0.681, respectively. Values for VIA with HPV triage were 39.6% (95% CI: 26.6-53.8%), 99.2% (95% CI: 98.8-99.5%), 45.2% (95% CI: 30.8-60.4%), 98.9% (95% CI: 98.5-99.3%), 1.5% (95% CI: 1.1-2.0%) and 0.694, respectively. VIA and HPV DNA co-test values were 100% (95% CI: 94.0-100%), 79.5% (95% CI: 78.0-81.0%), 8.0% (95% CI: 6.0-10.3%), 100% (95% CI: 99.9-100%), 21.9% (95% CI: 20.4-23.4%) and 0.898, respectively. VIA sensitivity decreases significantly in postmenopausal women compared to premenopausal performance. HPV DNA testing maintains performance between pre- and postmenopausal women and is the most accurate primary modality for screening postmenopausal populations in low resource areas of China. [ABSTRACT FROM AUTHOR]